Aurinia Pharmaceuticals(AUPH),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

AUPH Aurinia Pharmaceuticals

Closed 11-25 16:00:00 EST

8.71

-0.15

-1.69%

盘后8.73

+0.02+0.23%

19:59 EST

High9.00	Low8.69	Vol1.62M
Open8.94	D1 Closing8.86	Amplitude3.44%
Mkt Cap1.25B	Tradable Cap1.15B	Total Shares143.18M
T/O14.29M	T/O Rate1.23%	Tradable Shares131.67M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

{"stockData":{"symbol":"AUPH","market":"US","secType":"STK","nameCN":"Aurinia Pharmaceuticals","latestPrice":8.71,"timestamp":1732568400000,"preClose":8.86,"halted":0,"volume":1620585,"hourTrading":{"tag":"盘后","latestPrice":8.73,"preClose":8.71,"latestTime":"19:59 EST","volume":85472,"amount":744543.2824,"timestamp":1732582778949},"delay":0,"floatShares":131668028,"shares":143179269,"eps":-0.157225,"marketStatus":"Closed","change":-0.15,"latestTime":"11-25 16:00:00 EST","open":8.94,"high":8.995,"low":8.69,"amount":14293976.190345,"amplitude":0.034424,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-0.157225,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Market Trading","tradingStatus":1,"beginTime":1732611600000},"marketStatusCode":5,"adr":0,"adrRate":0,"listingDate":951454800000,"exchange":"NASDAQ","adjPreClose":8.86,"preHourTrading":{"tag":"盘前","latestPrice":8.9999,"preClose":8.86,"latestTime":"08:57 EST","volume":50,"amount":449.496,"timestamp":1732543068957},"postHourTrading":{"tag":"盘后","latestPrice":8.73,"preClose":8.71,"latestTime":"19:59 EST","volume":85472,"amount":744543.2824,"timestamp":1732582778949},"volumeRatio":1.046423,"impliedVol":0.628,"impliedVolPercentile":0.5159},"requestUrl":"/m/hq/s/AUPH/tweets","defaultTab":"tweets","newsList":[{"id":"2485766439","title":"Positive Outlook for Aurinia Pharmaceuticals Boosted by Favorable Lupus Nephritis Guidelines","url":"https://stock-news.laohu8.com/highlight/detail?id=2485766439","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2485766439?lang=en_us&edition=fundamental","pubTime":"2024-11-21 14:17","pubTimestamp":1732169845,"startTime":"0","endTime":"0","summary":"Leerink Partners analyst Joseph Schwartz has reiterated their bullish stance on AUPH stock, giving a Buy rating on November 19. Joseph Schwartz has...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/positive-outlook-for-aurinia-pharmaceuticals-boosted-by-favorable-lupus-nephritis-guidelines?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/positive-outlook-for-aurinia-pharmaceuticals-boosted-by-favorable-lupus-nephritis-guidelines?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","AUPH"],"gpt_icon":0},{"id":"2484939314","title":"Aurinia Pharmaceuticals Celebrates New Lupus Nephritis Guidelines","url":"https://stock-news.laohu8.com/highlight/detail?id=2484939314","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2484939314?lang=en_us&edition=fundamental","pubTime":"2024-11-19 07:42","pubTimestamp":1731973369,"startTime":"0","endTime":"0","summary":"Aurinia Pharmaceuticals (AUPH) has released an update. Aurinia Pharmaceuticals applauds the American College of Rheumatology’s 2024 guidelines for ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/aurinia-pharmaceuticals-celebrates-new-lupus-nephritis-guidelines?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/aurinia-pharmaceuticals-celebrates-new-lupus-nephritis-guidelines?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","AUPH"],"gpt_icon":0},{"id":"2484949938","title":"Aurinia Commends 2024 Updated Acr Guidelines for Screening, Treatment, and Management of Lupus Nephritis","url":"https://stock-news.laohu8.com/highlight/detail?id=2484949938","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2484949938?lang=en_us&edition=fundamental","pubTime":"2024-11-19 06:53","pubTimestamp":1731970380,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241118:nTUA17V9SP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["AUPH","BK4139"],"gpt_icon":0},{"id":"2484793306","title":"Aurinia Commends 2024 Updated ACR Guidelines for Screening, Treatment, and Management of Lupus Nephritis","url":"https://stock-news.laohu8.com/highlight/detail?id=2484793306","media":"Business Wire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2484793306?lang=en_us&edition=fundamental","pubTime":"2024-11-19 06:53","pubTimestamp":1731970380,"startTime":"0","endTime":"0","summary":"New Guidelines Presented at ACR Convergence 2024 Recommend First-Line Therapy with LUPKYNIS  as Part of a Triple Immunosuppressive LN Treatment Regimen. ROCKVILLE, Md. & EDMONTON, Alberta, November 18, 2024----Aurinia Pharmaceuticals Inc.   commends the American College of Rheumatology  for their 2024 evidence-based guidelines for the screening, treatment, and management of lupus nephritis , which prioritize the urgent need to use efficacious treatments to avoid nephron loss and preserve kidney function.The guidelines call for a triple immunosuppression treatment regimen for LN, with first line use of advanced therapies like LUPKYNIS for three to five years. Importantly, the guidelines suggest that steroids should be rapidly tapered to <5 mg/day by six months as the highest acceptable maintenance dose of steroids. The guidelines also call for achieving a proteinuria target of <0.5g/g urine protein creatinine ratio  by 12 months of treatment.The updated ACR guidelines for the diagnosis ","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/An4d8dQutE8atJF9tsuxdg--~B/aD01MTI7dz0xMDI0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/531a63b034674830bd95dad02710306d","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/An4d8dQutE8atJF9tsuxdg--~B/aD01MTI7dz0xMDI0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/531a63b034674830bd95dad02710306d"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/aurinia-commends-2024-updated-acr-225300348.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4007","BK4557","BK4110","ACB","ACR","BK4016","AUPH","BK4139","CNI"],"gpt_icon":1},{"id":"2483321924","title":"Aurinia Highlights Lupus Nephritis Breakthroughs at ACR 2024","url":"https://stock-news.laohu8.com/highlight/detail?id=2483321924","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483321924?lang=en_us&edition=fundamental","pubTime":"2024-11-15 19:35","pubTimestamp":1731670548,"startTime":"0","endTime":"0","summary":"Aurinia Pharmaceuticals (AUPH) has released an update. Aurinia Pharmaceuticals has unveiled new data underscoring the importance of early detection...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/aurinia-highlights-lupus-nephritis-breakthroughs-at-acr-2024?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/aurinia-highlights-lupus-nephritis-breakthroughs-at-acr-2024?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["AUPH","BK4110","BK4139","ACR"],"gpt_icon":0},{"id":"2483325151","title":"Aurinia Presents New Data Underscoring Critical Importance of Earlier Lupus Nephritis Detection and Intervention and Value of Lupkynis® in Managing Ln at American College of Rheumatology Convergence 2024","url":"https://stock-news.laohu8.com/highlight/detail?id=2483325151","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483325151?lang=en_us&edition=fundamental","pubTime":"2024-11-15 19:00","pubTimestamp":1731668400,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241115:nTUA3SJK5W:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["AUPH","BK4139"],"gpt_icon":0},{"id":"2483257393","title":"Aurinia Presents New Data Underscoring Critical Importance of Earlier Lupus Nephritis Detection and Intervention and Value of LUPKYNIS® in Managing LN at American College of Rheumatology Convergence 2024","url":"https://stock-news.laohu8.com/highlight/detail?id=2483257393","media":"Business Wire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483257393?lang=en_us&edition=fundamental","pubTime":"2024-11-15 19:00","pubTimestamp":1731668400,"startTime":"0","endTime":"0","summary":"ROCKVILLE, Md. & EDMONTON, Alberta, November 15, 2024----Aurinia Pharmaceuticals Inc.  , announced today the acceptance of four poster presentations at the annual American College of Rheumatology Convergence  2024 taking place in Washington, D.C., November 14-19. The data highlight the need for additional screening for lupus nephritis , a serious manifestation of systemic lupus erythematosus , and reinforce the clinical importance of LUPKYNIS , a second generation calcineurin inhibitor , for the treatment of adults with active LN.An analysis from the Phase 3 AURORA 1 and 2 studies highlighted the long-term efficacy of LUPKYNIS in people with LN. This study focused on a new efficacy endpoint, sustained complete renal response , defined by the United States Food and Drug Administration  as achieving a complete renal response  at 12 months in AURORA 1 and at all study visits in the 2-year AURORA 2 continuation study. Significantly more LUPKYNIS patients achieved SCRR compared to patients ","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/5E7r.Ca9i8SEtHG1_H3rTQ--~B/aD01MTI7dz0xMDI0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/8491453ee67c4f90fc15c15f7d4e54b6","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/5E7r.Ca9i8SEtHG1_H3rTQ--~B/aD01MTI7dz0xMDI0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/8491453ee67c4f90fc15c15f7d4e54b6"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/aurinia-presents-data-underscoring-critical-110000086.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4107","ACB","BK4117","BK4139","SLE","AFG","BK4077","BK4110","AUPH","BK4007","ACR","CNI","BK4557","BK4016"],"gpt_icon":1},{"id":"2482781429","title":"RBC Adjusts Aurinia Pharmaceuticals' Price Target to $9 From $8, Keeps Outperform Speculative Risk Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2482781429","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2482781429?lang=en_us&edition=fundamental","pubTime":"2024-11-11 21:32","pubTimestamp":1731331959,"startTime":"0","endTime":"0","summary":"Aurinia Pharmaceuticals (AUPH) has an average rating of outperform and price targets ranging from $8 to $13, according to analysts polled by Capital IQ.(MT Newswires covers equity, commodity and econo","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate","earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["AUPH"],"gpt_icon":0},{"id":"2482089207","title":"Aurinia Pharmaceuticals (AUPH) Gets a Buy from RBC Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2482089207","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2482089207?lang=en_us&edition=fundamental","pubTime":"2024-11-11 19:49","pubTimestamp":1731325753,"startTime":"0","endTime":"0","summary":"In a report released yesterday, Douglas Miehm from RBC Capital assigned a Buy rating to Aurinia Pharmaceuticals (AUPH – Research Report), with a pr...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/aurinia-pharmaceuticals-auph-gets-a-buy-from-rbc-capital-3?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/aurinia-pharmaceuticals-auph-gets-a-buy-from-rbc-capital-3?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["AUPH","BK4207","BK4139"],"gpt_icon":0},{"id":"2482527261","title":"Positive Outlook on Aurinia Pharmaceuticals Amid Strong Financial Performance and Strategic Cost Management","url":"https://stock-news.laohu8.com/highlight/detail?id=2482527261","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2482527261?lang=en_us&edition=fundamental","pubTime":"2024-11-11 16:35","pubTimestamp":1731314111,"startTime":"0","endTime":"0","summary":"Aurinia Pharmaceuticals (AUPH – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst David Martin...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/positive-outlook-on-aurinia-pharmaceuticals-amid-strong-financial-performance-and-strategic-cost-management?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/positive-outlook-on-aurinia-pharmaceuticals-amid-strong-financial-performance-and-strategic-cost-management?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","AUPH"],"gpt_icon":0},{"id":"2482487291","title":"Aurinia Pharmaceuticals: A Potential Buyout Looms On The Horizon","url":"https://stock-news.laohu8.com/highlight/detail?id=2482487291","media":"seekingalpha","labels":["analysis"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2482487291?lang=en_us&edition=fundamental","pubTime":"2024-11-09 01:15","pubTimestamp":1731086131,"startTime":"0","endTime":"0","summary":"Today, we are following up on biopharma name Aurinia Pharmaceuticals Inc.The company just posted solid Q3 results this week and announced significant cost reduction measures.Aurinia is seeing impressi","market":"hk","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/155151969/image_155151969.jpg","type":0,"news_type":0,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/155151969/image_155151969.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/article/4735001-aurinia-pharmaceuticals-a-potential-buyout-looms-on-the-horizon","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"analysis","news_rank":0,"length":0,"strategy_id":0,"source":"seekingalpha","symbols":["BK4139","AUPH"],"gpt_icon":0},{"id":"2481143287","title":"Aurinia Pharmaceuticals: Strong Q3 Performance and Promising Outlook Justify Buy Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2481143287","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481143287?lang=en_us&edition=fundamental","pubTime":"2024-11-08 15:31","pubTimestamp":1731051071,"startTime":"0","endTime":"0","summary":"Leerink Partners analyst Joseph Schwartz has reiterated their bullish stance on AUPH stock, giving a Buy rating yesterday. Joseph Schwartz has give...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/aurinia-pharmaceuticals-strong-q3-performance-and-promising-outlook-justify-buy-rating?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/aurinia-pharmaceuticals-strong-q3-performance-and-promising-outlook-justify-buy-rating?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["AUPH"],"gpt_icon":0},{"id":"2481665148","title":"Aurinia Pharmaceuticals Inc (AUPH) Q3 2024 Earnings Call Highlights: Strong Revenue Growth Amid ...","url":"https://stock-news.laohu8.com/highlight/detail?id=2481665148","media":"GuruFocus.com","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481665148?lang=en_us&edition=fundamental","pubTime":"2024-11-08 15:12","pubTimestamp":1731049942,"startTime":"0","endTime":"0","summary":"Total Net Revenue: $67.8 million for Q3 2024, up 24% from $54.5 million in Q3 2023.Net Product Revenue: $55.5 million for Q3 2024, up 36% from $40.8 million in Q3 2023.Cash Flow from Operations: $17 million generated in Q3 2024.Cash and Investments: $348.7 million as of September 30, 2024.Gross Margin: 91% for Q3 2024, compared to 88% in Q3 2023.SG&A Expenses: $42.4 million for Q3 2024, down from $47.8 million in Q3 2023.R&D Expenses: $3 million for Q3 2024, down from $13.6 million in Q3 2023.Net Income: $14.4 million for Q3 2024, or $0.10 per share, compared to a net loss of $13.4 million in Q3 2023.Patient Growth: 25% increase in total patients on LUPKYNIS therapy, with approximately 2,422 patients as of September 30, 2024.Restructuring Initiative: Workforce reduction by approximately 45%, with expected annualized cash-based operating expense savings of more than $40 million.GuruFocus has detected 5 Warning Signs with MTCH.Aurinia Pharmaceuticals Inc  reported a 24% increase in total","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/aurinia-pharmaceuticals-inc-auph-q3-071222281.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["AUPH"],"gpt_icon":0},{"id":"2481532581","title":"Aurinia stock jumps 14% on Q3 earnings, restructuring announcement","url":"https://stock-news.laohu8.com/highlight/detail?id=2481532581","media":"seekingalpha","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481532581?lang=en_us&edition=fundamental","pubTime":"2024-11-08 03:24","pubTimestamp":1731007441,"startTime":"0","endTime":"0","summary":"mohd izzuan Aurinia Pharmaceuticals (NASDAQ:AUPH) stock jumped 14% in afternoon trading Thursday after the company reported better-than-expected Q3 revenue and announced it was cutting around 45% of its workforce to focus on the commercialization of its lupus drug Lupkynis. For the third","market":"sh","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2155546094/image_2155546094.jpg?io=getty-c-w750","type":0,"news_type":0,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2155546094/image_2155546094.jpg?io=getty-c-w750"],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/news/4262333-aurinia-stock-jumps-on-q3-earnings-restructuring-announcement","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"seekingalpha_trending_news","symbols":["AUPH"],"gpt_icon":0},{"id":"2481132769","title":"Aurinia Pharmaceuticals Reports Q3 Beat, Plans to Cut Workforce by 45%; Shares Rise","url":"https://stock-news.laohu8.com/highlight/detail?id=2481132769","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481132769?lang=en_us&edition=fundamental","pubTime":"2024-11-07 23:41","pubTimestamp":1730994104,"startTime":"0","endTime":"0","summary":"Aurinia Pharmaceuticals  shares were up more than 10% in recent trading Thursday after the company reported better-than-expected Q3 net income and revenue.The company reported Q3 net income Thursday of $0.10 per diluted share, swinging from a net loss of $0.09 per share a year earlier.Analysts polled by Capital IQ expected earnings of $0.02 per share.Net revenue for the quarter ended Sept. 30 was $67.8 million, compared with $54.5 million a year earlier.Analysts polled by Capital IQ expected $57.7 million.The company said it will implement strategic restructuring, which includes reducing its workforce by about 45%, to focus on the commercial strategy for its Lupkynis treatment for lupus nephritis. This restructuring is estimated to yield over $40 million in annualized savings and $15 million to $19 million one-time charge in Q4.Price: 8.33, Change: +0.81, Percent Change: +10.77","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4139","AUPH"],"gpt_icon":0},{"id":"1100014185","title":"Stock Track | Aurinia Pharmaceuticals Soars on Stellar Q3 Results and Strategic Restructuring","url":"https://stock-news.laohu8.com/highlight/detail?id=1100014185","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1100014185?lang=en_us&edition=fundamental","pubTime":"2024-11-07 22:49","pubTimestamp":1730990969,"startTime":"0","endTime":"0","summary":"Aurinia Pharmaceuticals  stock surged over 7% in pre-market trading after the company reported impressive financial results for the third quarter of 2024 and announced a strategic restructuring plan.The biopharmaceutical firm reported adjusted earnings per share of $0.10 for Q3 2024, marking a remarkable 900% beat over the analyst consensus estimate of $0.01. Aurinia's quarterly revenue of $67.8 million also significantly exceeded Wall Street's expectations of $57.69 million, growing at a robust","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["AUPH"],"gpt_icon":0},{"id":"2481811581","title":"Unusually active option classes on open November 7th","url":"https://stock-news.laohu8.com/highlight/detail?id=2481811581","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481811581?lang=en_us&edition=fundamental","pubTime":"2024-11-07 22:47","pubTimestamp":1730990844,"startTime":"0","endTime":"0","summary":"Unusual total active option classes on open include: Aurinia Pharmaceuticals (AUPH), Baxter (BAX), Chevron (CVX), Warner Bros. Discovery (WBD), Dat...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/unusually-active-option-classes-on-open-november-7th-3?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/unusually-active-option-classes-on-open-november-7th-3?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4570","LU0417517546.SGD","LU0640476718.USD","BK4588","LU0208291251.USD","LU0868494708.USD","LU1303367103.USD","BK4592","IE00B3CCJ963.GBP","IE00BGHQF524.EUR","LU0070302665.USD","AUPH","BK4566","BK4585","LU0942090050.USD","BK4534","WBD","IE00B2Q91V27.USD","CVX","LU0098860793.USD","BK4082","BAX","LU1496350502.SGD","BK4581","BK4108","LU0310799852.SGD","LU0300736492.USD","LU0320765489.SGD","LU2098885051.SGD","LU0266512127.USD","BK4139","LU1267930490.SGD","LU2237438978.USD","LU0320765646.SGD","LU0211328371.USD","LU0368265418.SGD","LU0868494617.USD","LU0278409577.USD","BK4550","LU0300736062.USD","LU1074936037.SGD","LU0211327993.USD","LU0256863811.USD","BK4201","BK4559","LU0006061336.USD","LU1066051498.USD","LU1162221912.USD","LU1929549753.HKD","LU1496350171.SGD"],"gpt_icon":0},{"id":"2481186331","title":"Aurinia Pharmaceuticals Inc reports results for the quarter ended in January 1 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2481186331","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481186331?lang=en_us&edition=fundamental","pubTime":"2024-11-07 22:39","pubTimestamp":1730990340,"startTime":"0","endTime":"0","summary":"Aurinia Pharmaceuticals Inc reports results for the quarter ended in January 1 - Earnings Summary  Aurinia Pharmaceuticals Inc AUPH.OQ reported quarterly adjusted earnings of 10 cents per share for th","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241107:nL8N3ME2CZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AUPH"],"gpt_icon":0},{"id":"2481185242","title":"Aurinia Pharmaceuticals Shares up 7.4% After Co Announces Restructuring, Workforce Cut","url":"https://stock-news.laohu8.com/highlight/detail?id=2481185242","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481185242?lang=en_us&edition=fundamental","pubTime":"2024-11-07 22:34","pubTimestamp":1730990067,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241107:nFWN3ME1NT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["AUPH","BK4139"],"gpt_icon":0},{"id":"2481183777","title":"BUZZ-U.S. STOCKS ON THE MOVE-Guardant Health, AppLovin, Sarepta","url":"https://stock-news.laohu8.com/highlight/detail?id=2481183777","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481183777?lang=en_us&edition=fundamental","pubTime":"2024-11-07 22:22","pubTimestamp":1730989341,"startTime":"0","endTime":"0","summary":"BUZZ-U.S. STOCKS ON THE MOVE-Guardant Health, AppLovin, SareptaEikon search string for individual stock moves: STXBZThe Day Ahead newsletter: https://refini.tv/3LI4BU7The Morning News Call newsletter:","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241107:nL4N3ME1OR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EBS","SPCE","LU0787776722.HKD","WBUY","XPEV","TAP","BK4093","BAC","CTVA","AIZ","UAA","LOB","CLSK","SMC","HAL","BROS","LU","LU0306806265.USD","09868","LU0238689110.USD","GH","DJT","AUPH","CDLX","XELA","IE00B894F039.SGD","RIOT","SRPT","MTCH","GILD","BK1575","F","ELF","LU1894683348.USD","EVS.SI","MDJH","ACHR","MARA","TPR","BDX","MRNA","LU0648001328.SGD","BK4183","ZG","WOLF","LU0128525689.USD","APP","COIN","WBD","APPS"],"gpt_icon":1}],"profile":{"websiteUrl":"http://www.auriniapharma.com","stockEarnings":[{"period":"1week","weight":0.0911},{"period":"1month","weight":0.2675},{"period":"3month","weight":0.3107},{"period":"6month","weight":0.7006},{"period":"1year","weight":-0.0199},{"period":"ytd","weight":-0.0145}],"compareEarnings":[{"period":"1week","weight":0.0167},{"period":"1month","weight":0.0303},{"period":"3month","weight":0.0594},{"period":"6month","weight":0.1248},{"period":"1year","weight":0.3088},{"period":"ytd","weight":0.2529}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. The company also offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. Aurinia Pharmaceuticals Inc. is headquartered in Victoria, Canada.","yearOnYearQuotes":[{"month":1,"riseRate":0.4,"avgChangeRate":0.106403},{"month":2,"riseRate":0.5,"avgChangeRate":0.009372},{"month":3,"riseRate":0.4,"avgChangeRate":0.102117},{"month":4,"riseRate":0.6,"avgChangeRate":-0.012088},{"month":5,"riseRate":0.6,"avgChangeRate":-0.004093},{"month":6,"riseRate":0.4,"avgChangeRate":-0.030211},{"month":7,"riseRate":0.6,"avgChangeRate":0.036556},{"month":8,"riseRate":0.5,"avgChangeRate":-0.045687},{"month":9,"riseRate":0.5,"avgChangeRate":0.078058},{"month":10,"riseRate":0.545455,"avgChangeRate":0.035973},{"month":11,"riseRate":0.545455,"avgChangeRate":0.019351},{"month":12,"riseRate":0.4,"avgChangeRate":0.111111}],"exchange":"NASDAQ","name":"Aurinia Pharmaceuticals","nameEN":"Aurinia Pharmaceuticals"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Aurinia Pharmaceuticals(AUPH),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Aurinia Pharmaceuticals(AUPH) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Aurinia Pharmaceuticals,AUPH,Aurinia Pharmaceuticals股票,Aurinia Pharmaceuticals股票老虎,Aurinia Pharmaceuticals股票老虎国际,Aurinia Pharmaceuticals行情,Aurinia Pharmaceuticals股票行情,Aurinia Pharmaceuticals股价,Aurinia Pharmaceuticals股市,Aurinia Pharmaceuticals股票价格,Aurinia Pharmaceuticals股票交易,Aurinia Pharmaceuticals股票购买,Aurinia Pharmaceuticals股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Aurinia Pharmaceuticals(AUPH),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Aurinia Pharmaceuticals(AUPH) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}